FACS® Analysis of PBLs Comparing CD8+ T Cell–depleted with CD8+ T Cell–replete HN Groups
| . | . | CD8+CD3+ cells/CD3+cells (%) . | . | . | ||||
|---|---|---|---|---|---|---|---|---|
| Group . | . | 0 wk* . | . | 6 wk‡ . | . | 12 wk . | . | n . |
| CFA control | 23.15 ± 2.20 | 25.68 ± 1.38 | 24.63 ± 0.98 | 3 | ||||
| Normal HN | 25.53 ± 2.15 | 24.43 ± 1.91 | 25.35 ± 2.05 | 3 | ||||
| ATx/HN | 24.97 ± 0.84 | 22.14 ± 0.76 | 21.78 ± 0.77 | 5 | ||||
| Early CD8 depletion/HN | 0.47 ± 0.15§ | 0.40 ± 0.08§ | 1.01 ± 0.50§ | 5 | ||||
| Late CD8 depletion/HN | 22.57 ± 0.79 | 20.17 ± 2.07 | 1.04 ± 0.40§ | 5 | ||||
| . | . | CD8+CD3+ cells/CD3+cells (%) . | . | . | ||||
|---|---|---|---|---|---|---|---|---|
| Group . | . | 0 wk* . | . | 6 wk‡ . | . | 12 wk . | . | n . |
| CFA control | 23.15 ± 2.20 | 25.68 ± 1.38 | 24.63 ± 0.98 | 3 | ||||
| Normal HN | 25.53 ± 2.15 | 24.43 ± 1.91 | 25.35 ± 2.05 | 3 | ||||
| ATx/HN | 24.97 ± 0.84 | 22.14 ± 0.76 | 21.78 ± 0.77 | 5 | ||||
| Early CD8 depletion/HN | 0.47 ± 0.15§ | 0.40 ± 0.08§ | 1.01 ± 0.50§ | 5 | ||||
| Late CD8 depletion/HN | 22.57 ± 0.79 | 20.17 ± 2.07 | 1.04 ± 0.40§ | 5 | ||||
Prolonged CD8+ cell depletion was achieved with ATx followed by anti-CD8 mAb therapy (MRC OX-8). Values represent mean ± SEM, percentage total CD3+ cells (G4.18+) that are CD8+CD3+ (MRC OX-8+G4.18+).
Time of immunization.
Before CD8+ T cell depletion in group 5.
P < 0.0001 for comparisons with all CD8+ T cell replete groups. ANOVA followed by Bonferroni-Dunn post hoc multiple comparisons test.